Ijaz Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ijaz Ahmad has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Ikuo Tsunoda
Department of Microbiology, Kindai University Faculty of Medicine, Osaka 590-0197, Japan
7 shared publications - Ah-Mee Park
Department of Microbiology, Kindai University Faculty of Medicine, Osaka 590-0197, Japan
6 shared publications - Fumitaka Sato
Department of Microbiology, Kindai University Faculty of Medicine, Osaka 590-0197, Japan
6 shared publications - Seiichi Omura
Department of Science and Technology on Food Safety, Faculty of Biology-Oriented Science and Technology, Kindai University, Kinokawa 649-6493, Wakayama, Japan
5 shared publications - Sundar Khadka
Department of Microbiology, Kindai University Faculty of Medicine, Osaka 590-0197, Japan
4 shared publications - Sandesh Rimal
Department of Microbiology, Faculty of Medicine, Kindai University, Sakai 590-0197, Osaka, Japan
3 shared publications
Latest Publications
- Open Access
IgA Deficiency Exacerbates an Animal Model of Multiple Sclerosis Induced with Theiler’s Virus
Multiple sclerosis (MS) is an immune-mediated disease characterized by inflammatory demyelination and axonal degeneration in the central nervous system (CNS) and has been linked to viral infections. Theiler’s murine encephalomyelitis virus (TMEV) infection in SJL/J mice has been widely used as a viral model of MS, since TMEV-infected mice develop MS-like demyelination and axonal degeneration with viral persistence in the CNS. In the TMEV model, we previously demonstrated upregulation of immunoglobulin (Ig) A-related genes in the CNS, as well as IgA deposition and IgA-positive cell infiltration in demyelinating lesions. Although IgA has been implicated in the pathophysiology of MS, its precise role remains unclear. To determine the role of IgA in the TMEV model, we established IgA knockout (KO) mice on the SJL/J background; IgA KO mice lacked serum IgA and exhibited altered gut microbiota compositions. We found that TMEV-infected IgA KO mice developed more severe neurological signs than wild-type (WT) mice. IgA KO mice also had more severe inflammatory demyelination with higher levels of viral persistence and T cell infiltration in the CNS than WT mice. Immunologically, IgA KO mice mounted TMEV-specific lymphoproliferative responses and serum anti-viral antibody isotype titers, except for IgA, which were comparable to WT mice. Interleukin (IL)-17 and IL-10 productions were higher in IgA KO mice than in WT mice. Thus, IgA could play a protective role in the TMEV model in WT mice; IgA deficiency-mediated gut dysbiosis may contribute to enhanced immunopathology in IgA KO mice.
Open AccessIgA Deficiency Exacerbates an Animal Model of Multiple Sclerosis Induced with Theiler’s Virus
Multiple sclerosis (MS) is an immune-mediated disease characterized by inflammatory demyelination and axonal degeneration in the central nervous system (CNS) and has been linked to viral infections. Theiler’s murine encephalomyelitis virus (TMEV) infection in SJL/J mice has been widely used as a viral model of MS, since TMEV-infected mice develop MS-like demyelination and axonal degeneration with viral persistence in the CNS. In the TMEV model, we previously demonstrated upregulation of immunoglobulin (Ig) A-related genes in the CNS, as well as IgA deposition and IgA-positive cell infiltration in demyelinating lesions. Although IgA has been implicated in the pathophysiology of MS, its precise role remains unclear. To determine the role of IgA in the TMEV model, we established IgA knockout (KO) mice on the SJL/J background; IgA KO mice lacked serum IgA and exhibited altered gut microbiota compositions. We found that TMEV-infected IgA KO mice developed more severe neurological signs than wild-type (WT) mice. IgA KO mice also had more severe inflammatory demyelination with higher levels of viral persistence and T cell infiltration in the CNS than WT mice. Immunologically, IgA KO mice mounted TMEV-specific lymphoproliferative responses and serum anti-viral antibody isotype titers, except for IgA, which were comparable to WT mice. Interleukin (IL)-17 and IL-10 productions were higher in IgA KO mice than in WT mice. Thus, IgA could play a protective role in the TMEV model in WT mice; IgA deficiency-mediated gut dysbiosis may contribute to enhanced immunopathology in IgA KO mice.
- Open Access
The Safety of Alcaligenes Lipid A in a Virus-Induced Immune Disease Model Associated with IgA, Th17 Cells, and Microbiota
Lipid A is a component of lipopolysaccharide (LPS) of Gram-negative bacteria. Previously, we demonstrated that synthesized lipid A derived from Alcaligenes faecalis (ALA) could enhance antigen-specific immunoglobulin (Ig) A and T helper (Th) 17 responses, when ALA was co-administered experimentally with an antigen as a vaccine adjuvant. This raised concerns about the safety of the ALA usage, since IgA and Th17 responses have been suggested to play a pathogenic role in several immune-mediated diseases, including multiple sclerosis (MS). We investigated whether ALA administrations could exacerbate an animal model of MS, Theiler’s murine encephalomyelitis virus (TMEV) infection. TMEV-infected SJL/J mice were administered ALA at various time points, and their neurological signs were observed for 7 weeks. We found that ALA administrations did not exacerbate TMEV-induced inflammatory disease or viral persistence in the central nervous system (CNS), clinically or histologically. Furthermore, ALA administrations did not enhance TMEV-specific humoral and cellular responses, including IgA and Th17 responses. On the other hand, principal component analysis (PCA) of the fecal, not the ileal, samples showed significant changes in the microbiota, characterized by increases in the relative abundance of bacteria belonging to the phylum Bacteroidota, including the genera Alistipes and Bacteroides. Therefore, ALA injections could be safe for use in immune-mediated diseases, whose immunopathology has been associated with IgA and Th17 responses.
Open AccessThe Safety of Alcaligenes Lipid A in a Virus-Induced Immune Disease Model Associated with IgA, Th17 Cells, and Microbiota
Lipid A is a component of lipopolysaccharide (LPS) of Gram-negative bacteria. Previously, we demonstrated that synthesized lipid A derived from Alcaligenes faecalis (ALA) could enhance antigen-specific immunoglobulin (Ig) A and T helper (Th) 17 responses, when ALA was co-administered experimentally with an antigen as a vaccine adjuvant. This raised concerns about the safety of the ALA usage, since IgA and Th17 responses have been suggested to play a pathogenic role in several immune-mediated diseases, including multiple sclerosis (MS). We investigated whether ALA administrations could exacerbate an animal model of MS, Theiler’s murine encephalomyelitis virus (TMEV) infection. TMEV-infected SJL/J mice were administered ALA at various time points, and their neurological signs were observed for 7 weeks. We found that ALA administrations did not exacerbate TMEV-induced inflammatory disease or viral persistence in the central nervous system (CNS), clinically or histologically. Furthermore, ALA administrations did not enhance TMEV-specific humoral and cellular responses, including IgA and Th17 responses. On the other hand, principal component analysis (PCA) of the fecal, not the ileal, samples showed significant changes in the microbiota, characterized by increases in the relative abundance of bacteria belonging to the phylum Bacteroidota, including the genera Alistipes and Bacteroides. Therefore, ALA injections could be safe for use in immune-mediated diseases, whose immunopathology has been associated with IgA and Th17 responses.
- 31 July 2025
- Published by MyJove Corporation
- No. 221,p. e68451
JoVE Video Dataset
Upper airway samples, including nasal lavage fluid (NLF) and nasal swabs, are useful in detecting pathogens, including viruses and bacteria, which can cause respiratory diseases. NLF has been used to examine cellular and humoral components in the respiratory system, for example, in evaluating the induction of immunoglobulin (Ig) A following mucosal vaccinations. In experimental rodents, the NLF samples can be collected by either the trans-pharyngeal or trans-tracheal route. Although the trans-pharyngeal route has been reported to be more efficient in collecting the NLF samples than the trans-tracheal route, the NLF samples collected by the trans-pharyngeal route were often contaminated with blood, affecting the levels of cellular and humoral contents in the original NLF samples. Thus, this study aimed to establish a novel NLF collection method in experimental mice to minimize blood contamination. Briefly, before the lower jaw of the mouse was separated, cotton balls were placed in the mouth to absorb blood. When the bleeding was stopped, the NLF samples were collected by inserting a micropipette into the choana and flushing with 200 µL of phosphate-buffered saline twice (final volume: 400 µL/mouse). To detect blood contamination, a simple and sensitive forensic luminol test that detects hemoglobin was used. The luminol test demonstrated that blood contamination was detectable in the NLF samples harvested by the conventional method (without cotton balls), but not those harvested by the novel method (with cotton balls). Due to the contamination of blood, the total IgA and IgG concentrations in the NLF samples were higher in the conventional method than in the novel method; blood has been known to contain much higher levels of IgA and IgG than NLF. Therefore, this unique method can be used as a simple and sensitive method to collect NLF samples from experimental mice to prevent blood contamination.
- 31 July 2025
- Published by MyJove Corporation
- No. 221,p. e68451
JoVE Video Dataset
Upper airway samples, including nasal lavage fluid (NLF) and nasal swabs, are useful in detecting pathogens, including viruses and bacteria, which can cause respiratory diseases. NLF has been used to examine cellular and humoral components in the respiratory system, for example, in evaluating the induction of immunoglobulin (Ig) A following mucosal vaccinations. In experimental rodents, the NLF samples can be collected by either the trans-pharyngeal or trans-tracheal route. Although the trans-pharyngeal route has been reported to be more efficient in collecting the NLF samples than the trans-tracheal route, the NLF samples collected by the trans-pharyngeal route were often contaminated with blood, affecting the levels of cellular and humoral contents in the original NLF samples. Thus, this study aimed to establish a novel NLF collection method in experimental mice to minimize blood contamination. Briefly, before the lower jaw of the mouse was separated, cotton balls were placed in the mouth to absorb blood. When the bleeding was stopped, the NLF samples were collected by inserting a micropipette into the choana and flushing with 200 µL of phosphate-buffered saline twice (final volume: 400 µL/mouse). To detect blood contamination, a simple and sensitive forensic luminol test that detects hemoglobin was used. The luminol test demonstrated that blood contamination was detectable in the NLF samples harvested by the conventional method (without cotton balls), but not those harvested by the novel method (with cotton balls). Due to the contamination of blood, the total IgA and IgG concentrations in the NLF samples were higher in the conventional method than in the novel method; blood has been known to contain much higher levels of IgA and IgG than NLF. Therefore, this unique method can be used as a simple and sensitive method to collect NLF samples from experimental mice to prevent blood contamination.
- 11 July 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 221,p. e68451
Murine Nasal Lavage Fluid Collection without Blood Contamination
Upper airway samples, including nasal lavage fluid (NLF) and nasal swabs, are useful in detecting pathogens, including viruses and bacteria, which can cause respiratory diseases. NLF has been used to examine cellular and humoral components in the respiratory system, for example, in evaluating the induction of immunoglobulin (Ig) A following mucosal vaccinations. In experimental rodents, the NLF samples can be collected by either the trans-pharyngeal or trans-tracheal route. Although the trans-pharyngeal route has been reported to be more efficient in collecting the NLF samples than the trans-tracheal route, the NLF samples collected by the trans-pharyngeal route were often contaminated with blood, affecting the levels of cellular and humoral contents in the original NLF samples. Thus, this study aimed to establish a novel NLF collection method in experimental mice to minimize blood contamination. Briefly, before the lower jaw of the mouse was separated, cotton balls were placed in the mouth to absorb blood. When the bleeding was stopped, the NLF samples were collected by inserting a micropipette into the choana and flushing with 200 µL of phosphate-buffered saline twice (final volume: 400 µL/mouse). To detect blood contamination, a simple and sensitive forensic luminol test that detects hemoglobin was used. The luminol test demonstrated that blood contamination was detectable in the NLF samples harvested by the conventional method (without cotton balls), but not those harvested by the novel method (with cotton balls). Due to the contamination of blood, the total IgA and IgG concentrations in the NLF samples were higher in the conventional method than in the novel method; blood has been known to contain much higher levels of IgA and IgG than NLF. Therefore, this unique method can be used as a simple and sensitive method to collect NLF samples from experimental mice to prevent blood contamination.
- 11 July 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 221,p. e68451
Murine Nasal Lavage Fluid Collection without Blood Contamination
Upper airway samples, including nasal lavage fluid (NLF) and nasal swabs, are useful in detecting pathogens, including viruses and bacteria, which can cause respiratory diseases. NLF has been used to examine cellular and humoral components in the respiratory system, for example, in evaluating the induction of immunoglobulin (Ig) A following mucosal vaccinations. In experimental rodents, the NLF samples can be collected by either the trans-pharyngeal or trans-tracheal route. Although the trans-pharyngeal route has been reported to be more efficient in collecting the NLF samples than the trans-tracheal route, the NLF samples collected by the trans-pharyngeal route were often contaminated with blood, affecting the levels of cellular and humoral contents in the original NLF samples. Thus, this study aimed to establish a novel NLF collection method in experimental mice to minimize blood contamination. Briefly, before the lower jaw of the mouse was separated, cotton balls were placed in the mouth to absorb blood. When the bleeding was stopped, the NLF samples were collected by inserting a micropipette into the choana and flushing with 200 µL of phosphate-buffered saline twice (final volume: 400 µL/mouse). To detect blood contamination, a simple and sensitive forensic luminol test that detects hemoglobin was used. The luminol test demonstrated that blood contamination was detectable in the NLF samples harvested by the conventional method (without cotton balls), but not those harvested by the novel method (with cotton balls). Due to the contamination of blood, the total IgA and IgG concentrations in the NLF samples were higher in the conventional method than in the novel method; blood has been known to contain much higher levels of IgA and IgG than NLF. Therefore, this unique method can be used as a simple and sensitive method to collect NLF samples from experimental mice to prevent blood contamination.
- Open Access
Gut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment
Viral infections have been associated with multiple sclerosis (MS), an immune-mediated disease in the central nervous system (CNS). Since Theiler’s murine encephalomyelitis virus (TMEV) can induce MS-like demyelination, TMEV infection is the most widely used viral model for MS. Although the precise pathophysiology is unknown, altered fecal bacterial populations were associated with distinct immune gene expressions in the CNS. We aimed to determine the role of gut microbiota in TMEV infection by administering an antibiotic cocktail in drinking water before (prophylactic administration) or after (therapeutic administration) TMEV infection. The antibiotic administration reduced total eubacteria, including the phyla Bacillota and Bacteroidota, but increased the phylum Pseudomonadata in feces. Prophylactic administration did not alter TMEV-induced inflammatory demyelination clinically or histologically, without changes in anti-viral IgG1/IgG2c levels or lymphoproliferative responses; therapeutic administration temporarily suppressed the neurological signs. Although antibiotic treatment had minimal effects on TMEV infection, adding metronidazole and ampicillin in drinking water substantially reduced water intake in the antibiotic group of mice, resulting in significant body weight loss. Since dehydration and stress could affect immune responses and gut microbiota, caution should be exercised when planning or evaluating the oral antibiotic cocktail treatment in experimental animals.
Open AccessGut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment
Viral infections have been associated with multiple sclerosis (MS), an immune-mediated disease in the central nervous system (CNS). Since Theiler’s murine encephalomyelitis virus (TMEV) can induce MS-like demyelination, TMEV infection is the most widely used viral model for MS. Although the precise pathophysiology is unknown, altered fecal bacterial populations were associated with distinct immune gene expressions in the CNS. We aimed to determine the role of gut microbiota in TMEV infection by administering an antibiotic cocktail in drinking water before (prophylactic administration) or after (therapeutic administration) TMEV infection. The antibiotic administration reduced total eubacteria, including the phyla Bacillota and Bacteroidota, but increased the phylum Pseudomonadata in feces. Prophylactic administration did not alter TMEV-induced inflammatory demyelination clinically or histologically, without changes in anti-viral IgG1/IgG2c levels or lymphoproliferative responses; therapeutic administration temporarily suppressed the neurological signs. Although antibiotic treatment had minimal effects on TMEV infection, adding metronidazole and ampicillin in drinking water substantially reduced water intake in the antibiotic group of mice, resulting in significant body weight loss. Since dehydration and stress could affect immune responses and gut microbiota, caution should be exercised when planning or evaluating the oral antibiotic cocktail treatment in experimental animals.
- Open Access
- 19 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3460
Exploring the Role of Platelets in Virus-Induced Inflammatory Demyelinating Disease and Myocarditis
Theiler’s murine encephalomyelitis virus (TMEV) infection has been used as a mouse model for two virus-induced organ-specific immune-mediated diseases. TMEV-induced demyelinating disease (TMEV-IDD) in the central nervous system (CNS) is a chronic inflammatory disease with viral persistence and an animal model of multiple sclerosis (MS) in humans. TMEV infection can also cause acute myocarditis with viral replication and immune cell infiltration in the heart, leading to cardiac fibrosis. Since platelets have been reported to modulate immune responses, we aimed to determine the role of platelets in TMEV infection. In transcriptome analyses of platelets, distinct sets of immune-related genes, including major histocompatibility complex (MHC) class I, were up- or downregulated in TMEV-infected mice at different time points. We depleted platelets from TMEV-infected mice by injecting them with platelet-specific antibodies. The platelet-depleted mice had significantly fewer viral antigen-positive cells in the CNS. Platelet depletion reduced the severities of TMEV-IDD and myocarditis, although the pathology scores did not reach statistical significance. Immunologically, the platelet-depleted mice had an increase in interferon (IFN)-γ production with a higher anti-TMEV IgG2a/IgG1 ratio. Thus, platelets may play roles in TMEV infection, such as gene expression, viral clearance, and anti-viral antibody isotype responses.
- 19 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3460
Open AccessExploring the Role of Platelets in Virus-Induced Inflammatory Demyelinating Disease and Myocarditis
Theiler’s murine encephalomyelitis virus (TMEV) infection has been used as a mouse model for two virus-induced organ-specific immune-mediated diseases. TMEV-induced demyelinating disease (TMEV-IDD) in the central nervous system (CNS) is a chronic inflammatory disease with viral persistence and an animal model of multiple sclerosis (MS) in humans. TMEV infection can also cause acute myocarditis with viral replication and immune cell infiltration in the heart, leading to cardiac fibrosis. Since platelets have been reported to modulate immune responses, we aimed to determine the role of platelets in TMEV infection. In transcriptome analyses of platelets, distinct sets of immune-related genes, including major histocompatibility complex (MHC) class I, were up- or downregulated in TMEV-infected mice at different time points. We depleted platelets from TMEV-infected mice by injecting them with platelet-specific antibodies. The platelet-depleted mice had significantly fewer viral antigen-positive cells in the CNS. Platelet depletion reduced the severities of TMEV-IDD and myocarditis, although the pathology scores did not reach statistical significance. Immunologically, the platelet-depleted mice had an increase in interferon (IFN)-γ production with a higher anti-TMEV IgG2a/IgG1 ratio. Thus, platelets may play roles in TMEV infection, such as gene expression, viral clearance, and anti-viral antibody isotype responses.
- Open Access
- 18 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (16) , 12937
Anti-Glycolipid Antibody Examination in Five EAE Models and Theiler’s Virus Model of Multiple Sclerosis: Detection of Anti-GM1, GM3, GM4, and Sulfatide Antibodies in Relapsing-Remitting EAE
Anti-glycolipid antibodies have been reported to play pathogenic roles in peripheral inflammatory neuropathies, such as Guillain–Barré syndrome. On the other hand, the role in multiple sclerosis (MS), inflammatory demyelinating disease in the central nervous system (CNS), is largely unknown, although the presence of anti-glycolipid antibodies was reported to differ among MS patients with relapsing-remitting (RR), primary progressive (PP), and secondary progressive (SP) disease courses. We investigated whether the induction of anti-glycolipid antibodies could differ among experimental MS models with distinct clinical courses, depending on induction methods. Using three mouse strains, SJL/J, C57BL/6, and A.SW mice, we induced five distinct experimental autoimmune encephalomyelitis (EAE) models with myelin oligodendrocyte glycoprotein (MOG)35–55, MOG92–106, or myelin proteolipid protein (PLP)139–151, with or without an additional adjuvant curdlan injection. We also induced a viral model of MS, using Theiler’s murine encephalomyelitis virus (TMEV). Each MS model had an RR, SP, PP, hyperacute, or chronic clinical course. Using the sera from the MS models, we quantified antibodies against 11 glycolipids: GM1, GM2, GM3, GM4, GD3, galactocerebroside, GD1a, GD1b, GT1b, GQ1b, and sulfatide. Among the MS models, we detected significant increases in four anti-glycolipid antibodies, GM1, GM3, GM4, and sulfatide, in PLP139–151-induced EAE with an RR disease course. We also tested cellular immune responses to the glycolipids and found CD1d-independent lymphoproliferative responses only to sulfatide with decreased interleukin (IL)-10 production. Although these results implied that anti-glycolipid antibodies might play a role in remissions or relapses in RR-EAE, their functional roles need to be determined by mechanistic experiments, such as injections of monoclonal anti-glycolipid antibodies.
- 18 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (16) , 12937
Open AccessAnti-Glycolipid Antibody Examination in Five EAE Models and Theiler’s Virus Model of Multiple Sclerosis: Detection of Anti-GM1, GM3, GM4, and Sulfatide Antibodies in Relapsing-Remitting EAE
Anti-glycolipid antibodies have been reported to play pathogenic roles in peripheral inflammatory neuropathies, such as Guillain–Barré syndrome. On the other hand, the role in multiple sclerosis (MS), inflammatory demyelinating disease in the central nervous system (CNS), is largely unknown, although the presence of anti-glycolipid antibodies was reported to differ among MS patients with relapsing-remitting (RR), primary progressive (PP), and secondary progressive (SP) disease courses. We investigated whether the induction of anti-glycolipid antibodies could differ among experimental MS models with distinct clinical courses, depending on induction methods. Using three mouse strains, SJL/J, C57BL/6, and A.SW mice, we induced five distinct experimental autoimmune encephalomyelitis (EAE) models with myelin oligodendrocyte glycoprotein (MOG)35–55, MOG92–106, or myelin proteolipid protein (PLP)139–151, with or without an additional adjuvant curdlan injection. We also induced a viral model of MS, using Theiler’s murine encephalomyelitis virus (TMEV). Each MS model had an RR, SP, PP, hyperacute, or chronic clinical course. Using the sera from the MS models, we quantified antibodies against 11 glycolipids: GM1, GM2, GM3, GM4, GD3, galactocerebroside, GD1a, GD1b, GT1b, GQ1b, and sulfatide. Among the MS models, we detected significant increases in four anti-glycolipid antibodies, GM1, GM3, GM4, and sulfatide, in PLP139–151-induced EAE with an RR disease course. We also tested cellular immune responses to the glycolipids and found CD1d-independent lymphoproliferative responses only to sulfatide with decreased interleukin (IL)-10 production. Although these results implied that anti-glycolipid antibodies might play a role in remissions or relapses in RR-EAE, their functional roles need to be determined by mechanistic experiments, such as injections of monoclonal anti-glycolipid antibodies.
- Open Access
- 29 April 2023
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 5 (2) , 145-149
A Case Report of Methicillin-Resistant Staph. aureus Coinfection in COVID-19 in the Intensive Care Unit
Bacterial co-infections in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia are not very common as the prevalence of co-infections with other respiratory viruses. The rate of bacterial co-infection in hospitalized patients infected with influenza is higher than 30%, whereas it is lower than 4% in hospitalized patients with SARS-CoV-2. Respiratory viral infections associated with bacterial co-infection have higher mortality and morbidity rates. The literature shows that most SARS-CoV-2 patients admitted to the hospital do not necessarily screen for bacterial infections and antimicrobial susceptibility. Therefore, clinicians' misdiagnosis of these co-infections can pose a significant risk to the lives of vulnerable patients with COVID-19. In that light, we presented a complicated case of methicillin-resistant Staphylococcus aureus.
- 29 April 2023
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 5 (2) , 145-149
Open AccessA Case Report of Methicillin-Resistant Staph. aureus Coinfection in COVID-19 in the Intensive Care Unit
Bacterial co-infections in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia are not very common as the prevalence of co-infections with other respiratory viruses. The rate of bacterial co-infection in hospitalized patients infected with influenza is higher than 30%, whereas it is lower than 4% in hospitalized patients with SARS-CoV-2. Respiratory viral infections associated with bacterial co-infection have higher mortality and morbidity rates. The literature shows that most SARS-CoV-2 patients admitted to the hospital do not necessarily screen for bacterial infections and antimicrobial susceptibility. Therefore, clinicians' misdiagnosis of these co-infections can pose a significant risk to the lives of vulnerable patients with COVID-19. In that light, we presented a complicated case of methicillin-resistant Staphylococcus aureus.
- Open Access
- 21 January 2023
- Published by The Running Line in Advancements in Life Sciences
- Vol. 9 (4) , 429-436
The Contagious Nature of SARS-CoV-2 Omicron Variant and Vaccine Efficacy
Background: Since the first COVID-19 outbreak, variants of SARS-CoV-2 have continued to dominate the global population. The repeated waves of emerging variants, each replacing the previous one with a greater rate of transmissibility and mutations, are the primary cause of the global pandemic. Public health concerns dramatically rose when a highly mutated variant (VOC) omicron (B.1.1.529) emerged in late 2021. omicron has more than 50 mutations, and over 30 mutations are in their spike protein that contributes to the virologic characteristics of the variant. Omicron is more contagious than previously reported SARS-CoV-2 strains and can re-infect people who have already contracted other SARS-CoV-2 infections. The variant has acquired a unique immune escape mechanism against monoclonal antibodies and vaccines. Currently, no therapeutic drug or vaccine is specifically available to prevent omicron infection and sublineage emergence. Method: The review was designed to search the recent research and literature and compile the most pertinent data on the virologic characteristics of the variant of concern. Result: The study reviewed and discussed the present prevalence, infectivity, dominance, immune evasion, therapeutic options, vaccine efficacy, and the future prospect of the omicron variant. Conclusion: Omicron variant has become a global public health concern due to the emergence of highly mutated sublineages. Developing variant-specific therapeutic drugs or vaccines is desirable to prevent the spread of these contagious variants globally.Keywords: COVID-19, SARS-CoV-2, Omicron variant, Vaccine efficacy, Immune evasion.
- 21 January 2023
- Published by The Running Line in Advancements in Life Sciences
- Vol. 9 (4) , 429-436
Open AccessThe Contagious Nature of SARS-CoV-2 Omicron Variant and Vaccine Efficacy
Background: Since the first COVID-19 outbreak, variants of SARS-CoV-2 have continued to dominate the global population. The repeated waves of emerging variants, each replacing the previous one with a greater rate of transmissibility and mutations, are the primary cause of the global pandemic. Public health concerns dramatically rose when a highly mutated variant (VOC) omicron (B.1.1.529) emerged in late 2021. omicron has more than 50 mutations, and over 30 mutations are in their spike protein that contributes to the virologic characteristics of the variant. Omicron is more contagious than previously reported SARS-CoV-2 strains and can re-infect people who have already contracted other SARS-CoV-2 infections. The variant has acquired a unique immune escape mechanism against monoclonal antibodies and vaccines. Currently, no therapeutic drug or vaccine is specifically available to prevent omicron infection and sublineage emergence. Method: The review was designed to search the recent research and literature and compile the most pertinent data on the virologic characteristics of the variant of concern. Result: The study reviewed and discussed the present prevalence, infectivity, dominance, immune evasion, therapeutic options, vaccine efficacy, and the future prospect of the omicron variant. Conclusion: Omicron variant has become a global public health concern due to the emergence of highly mutated sublineages. Developing variant-specific therapeutic drugs or vaccines is desirable to prevent the spread of these contagious variants globally.Keywords: COVID-19, SARS-CoV-2, Omicron variant, Vaccine efficacy, Immune evasion.
- Open Access
- 28 December 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 69 (3) , 397-404
Comparison of 3 Days Amoxicillin Versus 5 Days Co-Trimoxazole for Treatment of Fast-breathing Pneumonia by Community Health Workers in Children Aged 2–59 Months in Pakistan: A Cluster-randomized Trial
Background: Globally, most deaths due to childhood pneumonia occur at the community level. Some countries are still using oral co-trimoxazole, despite a World Health Organization recommendation of oral amoxicillin for the treatment of fast-breathing pneumonia in children at the community level. Methods: We conducted an unblinded, cluster-randomized, controlled-equivalency trial in Haripur District, Pakistan. Children 2–59 months of age with fast-breathing pneumonia were treated with oral amoxicillin suspension (50 mg/kg/day) for 3 days in 14 intervention clusters and oral co-trimoxazole suspension (8 mg trimethoprim/kg and 40 mg sulfamethoxazole/kg/day) for 5 days in 14 control clusters by lady health workers (LHW). The primary outcome was treatment failure by day 4 for intervention clusters and by day 6 for control clusters. The analysis was per protocol. Results: Out of the 15 749 cases enrolled in the study, 9153 cases in intervention and 6509 cases in control clusters were included in the analysis. Treatment failure rates were 3.6% (326) in intervention clusters and 9.1% (592) in control clusters. After adjusting for clustering, the risk of treatment failure was lower in intervention clusters (risk difference [RD] -5.5%, 95% confidence interval [CI] -7.4–-3.7%) than in control clusters. Children with incomplete adherence had a small increase in treatment failure versus those with complete adherence (RD 2.9%, 95% CI 1.6–4.1%). No deaths or serious adverse events occurred. Conclusions: A 3-day course of oral amoxicillin, administered by LHWs, is an effective and safe treatment for fast-breathing pneumonia in children 2–59 months of age. A shorter course of amoxicillin improves adherence to therapy, is low in cost, and puts less pressure on antimicrobial resistance. Clinical Trials Registration: ISRCTN10618300.
- 28 December 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 69 (3) , 397-404
Open AccessComparison of 3 Days Amoxicillin Versus 5 Days Co-Trimoxazole for Treatment of Fast-breathing Pneumonia by Community Health Workers in Children Aged 2–59 Months in Pakistan: A Cluster-randomized Trial
Background: Globally, most deaths due to childhood pneumonia occur at the community level. Some countries are still using oral co-trimoxazole, despite a World Health Organization recommendation of oral amoxicillin for the treatment of fast-breathing pneumonia in children at the community level. Methods: We conducted an unblinded, cluster-randomized, controlled-equivalency trial in Haripur District, Pakistan. Children 2–59 months of age with fast-breathing pneumonia were treated with oral amoxicillin suspension (50 mg/kg/day) for 3 days in 14 intervention clusters and oral co-trimoxazole suspension (8 mg trimethoprim/kg and 40 mg sulfamethoxazole/kg/day) for 5 days in 14 control clusters by lady health workers (LHW). The primary outcome was treatment failure by day 4 for intervention clusters and by day 6 for control clusters. The analysis was per protocol. Results: Out of the 15 749 cases enrolled in the study, 9153 cases in intervention and 6509 cases in control clusters were included in the analysis. Treatment failure rates were 3.6% (326) in intervention clusters and 9.1% (592) in control clusters. After adjusting for clustering, the risk of treatment failure was lower in intervention clusters (risk difference [RD] -5.5%, 95% confidence interval [CI] -7.4–-3.7%) than in control clusters. Children with incomplete adherence had a small increase in treatment failure versus those with complete adherence (RD 2.9%, 95% CI 1.6–4.1%). No deaths or serious adverse events occurred. Conclusions: A 3-day course of oral amoxicillin, administered by LHWs, is an effective and safe treatment for fast-breathing pneumonia in children 2–59 months of age. A shorter course of amoxicillin improves adherence to therapy, is low in cost, and puts less pressure on antimicrobial resistance. Clinical Trials Registration: ISRCTN10618300.